The latest news, research, and perspectives in multiple myeloma. Multiple myeloma is characterized by the proliferation of malignant plasma cells that accumulate in the bone marrow and produce abnormal immunoglobulin. Read more about the pathophysiology, diagnosis, staging, and treatment of myeloma.
Patrick DalyMyeloma | April 19, 2024
The FDA ODAC voted in favor of the use of MRD-negativity as an intermediate endpoint for accelerated approval in MM trials.
Read More
Kenneth Anderson, MDMyeloma | April 11, 2024
The “real revolution” in myeloma is in the immune therapies, Dr. Anderson said, such as bispecific T-cell engagers and ...
Melissa BadamoMyeloma | April 8, 2024
The overall response rate was 71%, and the most common side effects were CRS, neutropenia, and anemia.
Leah SherwoodMyeloma | April 7, 2024
Cilta-cel was previously approved by the FDA in relapsed or refractory MM after four or more prior lines of therapy.
Patrick DalyMyeloma | April 5, 2024
The expansion of the indication was supported by positive data from the KarMMa-3 study.
Blood Cancer TalksMyeloma | March 29, 2024
KarMMa-3 trial evaluated ide-cel in MM, while the CARTITUDE-4 trial evaluated cilta-cel in MM.
Melissa BadamoMyeloma | March 22, 2024
The approval was based on results from the KarMMa-3 study, which compared ide-cel with standard combination regimens.
Blood Cancers Today Staff WritersMyeloma | March 18, 2024
The 11-member panel of independent experts voted eight in favor and three against.
Blood Cancers Today Staff WritersMyeloma | March 15, 2024
The FDA Oncologic Drugs Advisory Committee voted to recommend approval of the supplemental BLA for cilta-cel in myeloma.
Melissa BadamoMyeloma | March 13, 2024
For Dr. Banerjee, this month is a call to action to mitigate global disparities in myeloma treatment.
Melissa BadamoMyeloma | March 12, 2024
S. Vincent Rajkumar, MD, a myeloma clinician and researcher, currently serves as a Professor of Medicine at the Mayo Clinic.
Melissa BadamoMyeloma | March 8, 2024
Sebia’s free light chain (FLC) kappa and lambda assays have 510(k) clearance.
Patrick DalyMyeloma | March 19, 2024
A phase I clinical trial on IDP-023 is currently enrolling patients.
Melissa BadamoMyeloma | February 27, 2024
The target action date for the FDA’s decision is August 22, 2024.
Melissa BadamoMyeloma | February 27, 2024
Adding elotuzumab to induction, consolidation, or maintenance treatment did not result in improved PFS or OS.
Melissa BadamoMyeloma | March 19, 2024
The study used public data from various online sources related to approved CAR-T therapies for MM.
Blood Cancers Today Staff WritersMyeloma | February 21, 2024
The sBLA was approved for a reduced dosing frequency of 1.5 mg/kg every two weeks in relapsed or refractory myeloma.
Shambavi Richard, MDTransplantation & Cellular Therapy | February 20, 2024
The mandate could affect moving CAR-T therapies into earlier lines of therapy for multiple myeloma.
Pieter Sonneveld, MD, PhDMyeloma | February 16, 2024
The addition of daratumumab to VRd induction and consolidation therapy and to lenalidomide maintenance therapy improved PFS.
Patrick DalyMyeloma | February 27, 2024
Belamaf, bortezomib, and dexamethasone improved survival versus daratumumab bortezomib, and dexamethasone in myeloma.
Editorial Board